Eure KARE invests in Europe, the UK, and Israel to unlock the potential of synthetic biology and microbiome research. The firm believes these fields can address critical global challenges—from healthcare innovations like cell therapies and gene therapies to environmental solutions such as biofuels and pollution control—by commercializing Europe’s strong scientific research base and creating new industries.
Preferred startup development maturity for initial funding deployment.
Cutting-edge synthetic biology and microbiome technologies with applications in healthcare, agriculture, energy, and environmental sustainability.
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...
